-

Carl Haney, Executive Vice President, Global Innovation and Research & Development to Depart The Estée Lauder Companies

NEW YORK--(BUSINESS WIRE)--Today, The Estée Lauder Companies Inc. (NYSE: EL) announced that Carl Haney, Executive Vice President, Global Innovation and Research & Development (R&D), will depart the company effective June 30, 2025 to pursue new opportunities. With Carl’s transition, the company intends to bring in new external talent to drive the next era of transformative innovation in line with its strategic vision of becoming the best, most consumer-centric, prestige beauty company in the world.

“Over the past decade, Carl has forged impactful partnerships at the forefront of scientific innovation and delivered breakthrough products and superior formulations across categories, benefits and occasions, while fueling corporate innovation and advanced technologies,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “As we look to the future and delivering our bold Beauty Reimagined vision, we will transform our approach to innovation across the company—which includes evolving the structure of our R&D team, expanding our external partnerships, strengthening product and commercial innovation and accelerating speed-to-market.”

Mr. Haney joined The Estée Lauder Companies in 2012 following a more than 25-year R&D career at The Procter & Gamble Company. Throughout his tenure at The Estée Lauder Companies, Carl and his team have advanced end-to-end product and corporate innovation by strengthening the company’s global R&D network, enhancing scientific credentialing, expanding local relevancy, building upstream active ingredient and fermentation platforms, and significantly increasing the company’s global patent portfolio. Under his leadership, the company has also accelerated sustainability efforts at the company through sustainable packaging and green chemistry advancements. Most recently, Mr. Haney and his R&D team have unveiled new collaborations at the forefront of biotech innovation, longevity, active derma and other critical areas with best-in-class academic partners including the Massachusetts Institute of Technology and Serpin Pharma, and diverse industries such as pharma to fuel new product pipelines. Previously, Carl played a critical role as Chair of the company’s Global Crisis Leadership Team, overseeing planning and response for emerging issues, current issues, and crises globally.

During this transition, Mr. Haney and the R&D team will prioritize business continuity and enabling transformative innovation. Brand and regional leadership will collaborate with their R&D partners across the company’s robust innovation network until a successor is named.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s strategy, including Beauty Reimagined and the profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent filings with the Securities and Exchange Commission. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.

About The Estée Lauder Companies

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

ELC-C
ECL-L

Contacts

Media Relations:
Jill Marvin
jimarvin@estee.com

Investor Relations:
Rainey Mancini
rmancini@estee.com

The Estée Lauder Companies Inc.

NYSE:EL


Contacts

Media Relations:
Jill Marvin
jimarvin@estee.com

Investor Relations:
Rainey Mancini
rmancini@estee.com

More News From The Estée Lauder Companies Inc.

The Estée Lauder Companies to Participate in the Morgan Stanley Luxury Conference

NEW YORK--(BUSINESS WIRE)--Stéphane de La Faverie, President and Chief Executive Officer, and Nadine Graf, President, EMEA, UK&I, and Emerging Markets, of The Estée Lauder Companies Inc. (NYSE: EL) will participate in the Morgan Stanley Luxury Conference 2026 in Paris on Tuesday, May 19, 2026, at 4:00 p.m. CEST. Interested parties can access the live webcast of the fireside chat on Tuesday, May 19th from 4:00 p.m. – 4:45 p.m. CEST at http://www.elcompanies.com/investors. The webcast will be...

The Estée Lauder Companies Reports Fiscal 2026 Third Quarter Results

NEW YORK--(BUSINESS WIRE)--The Estée Lauder Companies Inc. (NYSE: EL) today reported its financial results for the third quarter ended March 31, 2026. “Our third quarter results extend strong year-to-date performance, driven by Beauty Reimagined,” said Stéphane de La Faverie, President and CEO. “In the first nine months of fiscal 2026, organic sales for Fragrance rose double-digits, while three of four regions grew, led by high single-digit growth in Mainland China where we outperformed prestig...

The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN

NEW YORK--(BUSINESS WIRE)--The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to sup...
Back to Newsroom